What is Novavax's D&A?

Novavax (NVAX) reported D&A of $3.06M in Q1 2026.

How has Novavax's D&A changed year-over-year?

Novavax's D&A decreased by 63.3% year-over-year, from $8.34M to $3.06M.

What is the long-term trend for Novavax's D&A?

Over 4 years (2021 to 2025), Novavax's D&A has grown at a 21.5% compound annual growth rate (CAGR), from $12.66M to $27.61M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Novavax NVAX D&A

D&A at other companies

ModernaMRNA

$59M+51.3%

Roivant SciencesROIV

$638K-55.2%

Vaxcyte, Inc.PCVX

$2.95M-0.3%

Viridian Therapeutics, Inc.VRDN

$121K+3.4%

ALN

Alnylam PharmaceuticalsALNY

$13.55M-5.9%

Nektar TherapeuticsNKTR

$151K-64.6%

Other financials

Income statement

See full

Revenue$139.5M-79.1%

Gross profit$108.8M-83.3%

Operating income-$15.4M-103%

Net income-$9.5M-102%

EPS (diluted)-$0.06-102%

Balance sheet

See full

Cash & equivalents$228.4M-13.3%

Total debt$295.1M+404%

Total equity-$144.8M-91.4%

Total assets$1.0B-19.3%

Cash flow

See full

Operating cash flow-$32.4M+82.5%

CapEx$1.3M-20.4%

Free cash flow-$33.7M+82.0%

Valuation

See full

Market cap$1.46B+41.0%

Enterprise value$1.53B+83.6%

P/S2.5×+1.6×

Profitability

See full

Gross margin85%-2.5pp

Operating margin-13.1%-45.9pp

Net margin-14.7%-52.9pp

FCF margin-58.9%-61.4pp

Returns & leverage

See full

Return on equity-238.6%—

Debt / equity1.5×—

Current ratio2.5×+0.4×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Novavax's D&A?: Novavax (NVAX) reported D&A of $3.06M in Q1 2026.
How has Novavax's D&A changed year-over-year?: Novavax's D&A decreased by 63.3% year-over-year, from $8.34M to $3.06M.
What is the long-term trend for Novavax's D&A?: Over 4 years (2021 to 2025), Novavax's D&A has grown at a 21.5% compound annual growth rate (CAGR), from $12.66M to $27.61M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.